Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2024-04-19 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
监事会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Harbin Yuheng Pharmaceutical Co., Ltd. It details the approval of various reports and proposals related to the 2023 fiscal year, including the 2023 Annual Report, financial statements, Supervisory Board work report, internal control evaluation report, profit distribution plan, and other governance matters. The document repeatedly states that these items are subject to approval at the 2023 Annual General Meeting and refers to the full reports being disclosed separately on official media platforms. The document itself is a formal announcement of the Supervisory Board's meeting resolutions rather than the full reports or financial statements. The length is 4225 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports the resolutions and voting outcomes of the Supervisory Board meeting related to the annual reports and other matters to be approved by shareholders.
2024-04-19 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the 6th Board of Directors of Harbin Yuheng Pharmaceutical Co., Ltd. It includes approvals of the 2023 annual report, financial statements, board work report, internal control evaluation, profit distribution plan, remuneration for directors and senior management, financing credit limits, and amendments to the company charter and various management systems. It also discusses the appointment of the external auditor for 2024 and the scheduling of the 2023 annual shareholders meeting. The document is not the annual report itself but a board meeting resolution announcement that references the annual report and other reports disclosed elsewhere. It contains detailed board decisions and voting results, focusing on governance, remuneration, and financial matters requiring shareholder approval. This fits the category of Board/Management Information (MANG) as it announces board meeting resolutions and management decisions rather than the full annual report or financial statements. The document length and content confirm it is not a brief announcement or a certification but a substantive board meeting resolution announcement.
2024-04-19 Chinese
年度关联方资金占用专项审计报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report issued by a certified public accounting firm regarding the 2023 non-operating fund occupation and other related party fund transactions of Harbin Yuheng Pharmaceutical Co., Ltd. It references the audit of the 2023 financial statements and provides a specific audit opinion on a summary table prepared by management about non-operating fund occupation and related party transactions. The document includes detailed audit procedures and compliance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. It is not a full annual report but a standalone audit report focused on a specific aspect of the company's financials, namely non-operating fund occupation and related party transactions. Therefore, it fits the category of an Audit Report / Information (AR). The document length (15,000 characters) and detailed content support this classification with high confidence. FY 2023
2024-04-19 Chinese
2023年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2023年度董事会工作报告' which translates to '2023 Annual Board of Directors Work Report'. It details the activities, meetings, and resolutions of the board of directors throughout the year 2023, including the number of meetings, agenda items, and governance improvements. It also outlines plans for 2024. The content focuses on the board's work and governance rather than full financial statements or audit results. There is no indication that this is an annual report (10-K) or an audit report (AR). It is a detailed report on board and management activities, consistent with the category 'Board/Management Information (MANG)'. The document length is sufficient and contains substantive content about board activities, not just an announcement or summary, so it is not an RPA or RNS. Therefore, the best classification is MANG with high confidence.
2024-04-19 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled "2023 年年度报告" which translates to "2023 Annual Report". It contains detailed sections typical of an annual report such as a letter to shareholders, company overview, management discussion and analysis, financial data, and corporate governance information. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. It includes audited financial data, management commentary, and comprehensive business information for the fiscal year 2023. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-19 Chinese
关于使用闲置自有资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the use of idle funds for entrusted financial management. It details the board meeting resolution, the purpose, scope, risk control measures, and impact of the entrusted financial management. The document is relatively short (1778 characters) and does not contain financial statements or detailed financial data. It is an announcement of a financing-related decision rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities related to the use of idle funds for financial products.
2024-04-19 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.